Skip to main content

Table 3 Incidence of Treatment-related Adverse Events in the Study Population for Each Cohort

From: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Adverse Event

NCI CTC Severity Grade

Dose Cohort

Total

  

250 mg

500 mg

750 mg

850 mg

1000 mg

  
  

No.

%

No.

%

No.

%

No.

%

No.

%

No.

%

Hypertension

1-2

2

50

7

63.6

9

60

9

69.2

2

66.7

29

63

 

3-4

-

-

  

2

13.3

-

-

1

33.3

3

6.5

Proteinuria

1-2

-

-

4

36.4

7

46.67

5

38.5

-

 

16

34.8

 

3-4

1

25.0

1

9

3

20

1

7.7

-

-

6

13

Hand-Food Syndrome

1-2

-

-

4

36.4

7

46.7

4

30.8

-

-

15

32.6

 

3-4

-

-

1

9

2

13.3

2

15.4

1

33.3

6

13

Pain

1-2

-

-

4

36.4

4

26.7

3

23.1

1

33.3

12

26.1

 

3-4

-

-

2

18.2

2

13.3

-

-

-

-

4

8.7

Thrombocytopenia

1-2

1

25.0

2

18.2

6

40

2

15.4

1

33.3

12

26.1

 

3-4

-

-

0

0

-

-

1

7.7

-

-

1

2.2

Fatigue

1-2

-

-

1

9

4

26.7

4

30.8

1

33.3

10

21.7

 

3-4

-

-

-

-

1

6.7

-

-

1

33.3

2

4.3

Hyperbilirubinemia

1-2

-

-

-

-

-

-

3

23.1

-

-

3

6.5

 

3-4

1

25

-

-

-

-

-

-

-

-

1

2.2

Transaminase Increased

1-2

2

50.0

1

9

6

40

3

23.1

1

33.3

13

28.3

 

3-4

-

-

1

9

-

-

2

15.4

1

33.3

4

8.7

Hemorrhage

1-2

-

-

4

36.4

5

33.3

1

7.7

-

-

10

21.7

 

3-4

-

-

1

9

-

-

-

-

-

-

1

2.2

Neutropenia

1-2

-

-

2

18.2

7

46.7

4

30.8

3

100

16

34.8

 

3-4

-

-

2

18.2

-

-

2

15.4

-

-

4

8.7

Diarrhea

1-2

-

-

1

9

3

20

2

15.4

-

-

6

13

 

3-4

-

-

-

-

-

-

-

-

-

-

-

-

Mucosal ulcers

1-2

-

-

2

18.2

2

13.3

2

15.4

2

66.7

8

17.4

 

3-4

-

-

-

-

2

13.3

-

-

-

-

2

4.3

Infection

1-2

1

25.0

1

9

4

26.7

3

23.1

1

33.3

10

21.7

 

3-4

-

-

-

-

-

-

-

-

-

-

-

-

Dyspnea

1-2

-

-

-

-

-

-

1

7.7

-

-

1

2.2

 

3-4

-

-

-

-

-

-

-

-

-

-

-

-

Vomiting

1-2

-

-

0

0

4

26.7

-

-

-

-

4

8.7

 

3-4

-

-

-

-

-

-

1

7.7

-

-

1

2.2

Hoarseness

1-2

-

-

1

9

2

13.3

1

7.7

-

-

4

8.7

 

3-4

-

-

-

-

-

-

-

-

-

-

-

-

Albinism

1-2

-

-

-

-

1

6.7

-

-

-

-

1

2.2

 

3-4

-

-

-

-

-

-

-

-

-

-

-

-

Anemia

1-2

1

25.0

1

9

3

20

2

15.4

-

-

7

15.2

 

3-4

-

-

-

-

-

-

1

7.7

1

33.3

2

4.3

Rash

1-2

-

-

1

9

1

6.7

1

7.7

-

-

3

6.5

 

3-4

-

-

-

-

-

-

-

-

-

-

-

-

Anorexia

1-2

-

-

2

18.2

3

20

1

7.7

1

33.3

7

15.2

 

3-4

-

-

-

-

-

-

-

-

-

-

-

-

  1. Abbreviations: AE, adverse event; NCI CTC, National Cancer Institute Common Toxicity Criteria
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us